Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07476313

Validation and Usability Study of the SleepView+ Home Sleep Testing System for the Evaluation of Moderate to Severe Obstructive Sleep Apnea.

The goal of this observational study is to characterize the performance of the SleepView+ home sleep test system for the evaluation of moderate to severe obstructuve sleep apnea (OSA) in adult and pediatric patients (ages 12 and over).

This study is being conducted in patients being evaluated for a sleep disorder who are scheduled to undergo an in lab polysomnigraphic study (PSG), enriching for suspected obstructive sleep apnea. This study will involve two phases:

A - comparison of SleepView+ detection of apneas and hypopneas to simultaneously collected in lab PSG (validation phase) and B - evaluation of the ability of patients to use the SleepView+ system in their home environment without sleep technologist support (usability phase)

Participants will progress from phase A to phase B.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Obstructive Sleep Apnea Apnea Dyssomnias Nervous System Diseases Respiration Disorders Respiratory Tract Diseases Sleep Apnea Syndromes Sleep Apnea, Obstructive Sleep Disorders, Intrinsic Sleep Wake Disorders

Age range

12 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Redwood Pulmonary Medical Associates, Redwood City, California, United States

Loading trial locations.

About this study

This study is a validation and usability study of the SleepView+ home sleep test for assessing obstructive sleep apnea. The SleepView+ device consists of multiple peripheral sensors that are designed to be placed by patients themselves. The system is intended to be operable by patients without technologist intervention.

The study will first evaluate the ability of SleepView+ to diagnose moderate to severe obstructive sleep apnea, as compared to in lab polysomnography. In a second usability phase, participants will take the SleepView+ device home and record a second night without technologist or expert supervision/assistance. Usability surveys and data quality metrics will be collected to assess the ability of participants (or their caregivers) to successfully operate the device in its intended at-home use.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥ 12 years of age
  • Referred to a sleep lab study site with a clinical indication for an overnight PSG (either full-night or split-night PSG/PAP titration sleep study)

Exclusion criteria

  • Age <12 yrs
  • Participants who cannot read written instructions in English, have significant cognitive impairment or are otherwise unable to provide informed consent
  • Concomitant enrollment in another study protocol that may interfere with data acquisition or reliability of measurements
  • Known to be pregnant at time of recruitment
  • Stroke or myocardial infarction within 6 months sleep study
  • Deemed unsuitable for selection by the research team or medical team due to any medical, legal, social, or interpersonal issues, that would either compromise the study or the routine care of patients.
  • Any other medical condition considered high risk or that may impact device usage, as determined by the site PI or medical monitor

Treatment and study plan

SleepView+

Device

Participants will wear the SleepView+ sleep monitor during both their in lab overnight PSG (for validation of apnea and hypopnea detection versus gold-standard clinical in-lab PSG), and then subsequently at home (to assess device usability).

Primary outcomes

  1. Diagnosis of moderate to severe obstructive sleep apnea (OSA)

    Time frame: 5 months

    SleepView+ derived apnea and hypopnea (over the total recording time) will be compared to in-lab PSG derived apnea and hypopnea count (over the total recording time) in order to determine the ability of the SleepView+ system to diagnose moderate to severe OSA. The primary endpoint will be positive percent agreement (PPA) and negative percent agreement (NPA) between SleepView+ diagnoses and in lab PSG. The passing criteria will be a lower bound of the 90% confidence interval of PPA exceeding 0.70 and a lower bound of the 90% confidence interval of NPA exceeding 0.70.

Secondary outcomes

  1. Usability metrics

    Time frame: 5 months

    Summary statistics of data quality of Phase B (at home) recordings and usability survey responses will be used to assess device usability.

  2. Diagnotic accuracy for mild OSA

    Time frame: 5 months

    Subgroup analysis will be performed on participants diagnosed with mild OSA (Apnea-Hypopnea Index of 5-15). Identical non-inferiority analyses will be conducted on the apnea and hypopnea indices from SleepView+ as compared to in-lab PSG in this cohort.

  3. Diagnostic accuracy for severe OSA

    Time frame: 5 months

    Subgroup analysis will be performed on participants diagnosed with severe OSA (Apnea-Hypopnea Index of >30). Identical non-inferiority analyses will be conducted on the apnea and hypopnea indices from SleepView+ as compared to in-lab PSG in this cohort.

Sponsors and collaborators

Lead sponsor

Beacon Biosignals

Industry

Registry information

Official study title

SleepView+ Validation Testing

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Mar 17, 2026
Registry last updated
Mar 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.